Stentys €40m rights issue lets FSI and funds in
Stentys, a biotechnology company with a focus on heart problems, launched a €36.4m rights issue on Tuesday, which will allow for a reorganisation of shareholders with the French Fonds Stratégique d’Investissement (FSI) joining the register.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: